Evidence map›Paper›PMID 33302945›Full record

ArticleBMC complementary medicine and therapies2020

Selective cytotoxic and anti-metastatic activity in DU-145 prostate cancer cells induced by Annona muricata L. bark extract and phytochemical, annonacin.

Kimberley Foster, Omolola Oyenihi, Sunelle Rademan, Joseph Erhabor, Motlalepula Matsabisa, James Barker, Moses K Langat, Amy Kendal-Smith, Helen Asemota, Rupika Delgoda

Open access · goldAbstract read
In one paragraph

Article in BMC complementary medicine and therapies, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Assessment of Anticancer Properties ofPlants (Basel, Switzerland) · 2024
    Article
  5. Article
  6. Anticancer acumens of three Annona species: a proportional review.Journal of cancer research and clinical oncology · 2023
    Review
  7. Review
  8. A Review onCancers · 2022
    Review
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 3 countries.

Kimberley FosterNatural Products Institute, University of the West Indies, Mona, Kingston 7, Jamaica.
Omolola OyenihiPharmacology Department, School of Clinical Medicine, Faculty of Health Sciences, University of the Free State, Bloemfontein, South Africa.
Sunelle RademanPharmacology Department, School of Clinical Medicine, Faculty of Health Sciences, University of the Free State, Bloemfontein, South Africa.
Joseph ErhaborPharmacology Department, School of Clinical Medicine, Faculty of Health Sciences, University of the Free State, Bloemfontein, South Africa.
Motlalepula MatsabisaPharmacology Department, School of Clinical Medicine, Faculty of Health Sciences, University of the Free State, Bloemfontein, South Africa.
James BarkerSchool of Life Sciences, Pharmacy and Chemistry, Kingston University, Penrhyn Road, Kingston-upon-Thames, Surrey, UK.
Moses K LangatJodrell Laboratory, Department of Natural Capital and Plant Health, Royal Botanic Gardens, Kew, Richmond, TW9 3DS, UK.
Amy Kendal-SmithJodrell Laboratory, Department of Natural Capital and Plant Health, Royal Botanic Gardens, Kew, Richmond, TW9 3DS, UK.
Helen AsemotaBiotechnolgy Centre, University of the West Indies, Mona, Kingston 7, Jamaica.
Rupika DelgodaNatural Products Institute, University of the West Indies, Mona, Kingston 7, Jamaica. thejani.delgoda@uwimona.edu.jm.ORCID http://orcid.org/0000-0002-6100-481X
University of the Free State · ZAUniversity of the West Indies System · JMKingston University · GBRoyal Botanic Gardens, Kew · GBUniversity of Leeds · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAnnona muricata L. was identified as a popular medicinal plant in treatment regimens among cancer patients in Jamaica by a previously conducted structured questionnaire. Ethnomedically used plant parts, were examined in this study against human prostate cancer cells for the first time and mechanisms of action elucidated for the most potent of them, along with the active phytochemical, annonacin.

methodsNine extracts of varying polarity from the leaves and bark of A. muricata were assessed initially for cytotoxicity using the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay on PC-3 prostate cancer cells and the ethyl acetate bark (EAB) extract was identified as the most potent. EAB extract was then standardized for annonacin content using High-performance Liquid Chromatography - Mass Spectrometry (HPLC-MS) and shown to be effective against a second prostate cancer cell line (DU-145) also. The mode of cell death in DU-145 cells were assessed via several apoptotic assays including induction of increased reactive oxygen species (ROS) production, reduction of mitochondrial membrane potential, activation of caspases and annexin V externalization combined with morphological observations using confocal microscopy. In addition, the potential to prevent metastasis was examined via inhibition of cell migration, vascular endothelial growth factor (VEGF) and angiogenesis using the chorioallantoic membrane assay (CAM).

resultsAnnonacin and EAB extract displayed selective and potent cytotoxicity against the DU-145 prostate carcinoma cells with IC

conclusionsTaken together, the standardized EAB extract and annonacin appear to induce selective and potent cell death via a necrotic pathway in DU-145 cells, while also preventing cell migration and angiogenesis, which warrant further examinations for mechanistic insights and validity in-vivo.

Indexed as

AnnonaAntineoplastic AgentsCarcinomaCaspasesCell Line, TumorCell MovementDocetaxelDrug Screening Assays, AntitumorDrug Therapy, CombinationFuransHumansLactonesMaleMembrane Potential, MitochondrialPhytotherapyPlant BarkannonacinAntineoplastic AgentsCaspasesDocetaxelFuransLactonesPlant ExtractsReactive Oxygen SpeciesAnnonacinAnnona muricata LAntiangiogenesisCaspaseDocetaxelEthnopharmacologyProstate cancerROS

Identifiers

PMID33302945
PMCPMC7727144
OpenAlexW3112379587

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.